Delivery Order SPE2DB22D3009-SPE2DB24FAU23

Award Date 4/15/24
Potential Completion Date 5/6/24
Potential Value $5.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of BOTOX 200 UNIT VIALS to the Defense Logistics Agency (DLA), a defense agency. The contract, a Delivery Order valued at $5,239.17, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award has a firm fixed-price pricing type and an ultimate completion date of November 29, 2024. This contract is not designated with a set-aside requirement, indicating open competition....
This federal contract award is for the delivery of 200-unit vials of Botox to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The contract, valued at $11,642.60, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of August 5, 2024. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a for-profit subsidiary of Amerisourcebergen Corporation that serves as a prime contractor providing pharmaceutical products and medical supplies to U.S. government agencies. The award is a firm fixed price delivery order for 4,563,856,643 units of BOTOX 200 with a potential value of $3,492.78 and a performance period through March 22, 2024. This award is not associated with any set-aside...
This federal contract award is for the delivery of BOTOX 200 unit vials to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for a ceiling value of $6,985.56. The contract has a firm fixed price pricing type and a completion date of July 23, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award is for the delivery of BOTOX 200 UNIT VIALS to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on January 8, 2025, with a ceiling value of $8,547.90 and a completion date of January 30, 2025. The contract is a Delivery Order with a Firm Fixed Price pricing type. The award is not associated with a set-aside designation, indicating open...
This federal contract award is for the delivery of BOTOX 100 unit vials to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, and has a ceiling value of $8,613.60. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and has an ultimate completion date of February 19, 2025. The contract is not designated as a set-aside award. Amerisourcebergen...
This federal contract award is for the delivery of BOTOX 200 unit vials to the Defense Logistics Agency (DLA), a defense agency that supports military healthcare programs. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price of $14,454.00 and a completion date of December 31, 2024. This award does not have a set-aside designation, indicating open competition....
This federal contract award is for the delivery of BOTOX 200 UNIT VIALS to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $13,971.12 and a completion date of May 23, 2024. The place of performance is Conshohocken, PA. This...
This federal contract award is for the delivery of BOTOX 200 UNIT VIALS to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on December 16, 2024, with a ceiling value of $3,613.50 and an ultimate completion date of January 8, 2025. The contract is a Delivery Order under a Firm Fixed Price pricing type. The contract does not have a set-aside designation, indicating...
This federal contract award is for the supply of BOTOX 200 UNIT VIALS to the U.S. Department of Defense (DoD), specifically the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $2,910.65, was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distribution company. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00, which serves as the primary...
  • SPE2DB22D3009
    Indefinite Delivery Contract
  • SPE2DB22D3009-SPE2DB24FAU23
    Delivery Order

This federal contract award is for the provision of BOTOX 200 UNIT VIALS to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense (DoD). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, under a Delivery Order valued at $5,821.30. The award has an ultimate completion date of May 6, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to provide a wide range of pharmaceutical products and medical supplies to support DoD medical programs and facilities globally. This contract does not have a set-aside designation.

Generated 7/15/24, 6:40 PM